The replacement of a necrotic tubular epithelium with functional tubular epithelial cells is required for recovery from acute renal failure (ARF). A rat renal progenitor-like (rKS56) cell line was recently established derived from the S3 segment of renal proximal tubules. The therapeutic efficacy of rKS56 cells was examined in a rat model of cisplatin-induced ARF. rKS56-lacZ cells expressing β-galactosidase were injected into SD rats either at the subcapsule of the left kidney (rKS-SC) or via the left renal artery (rKS-IA) 2 days after the injection of cisplatin. Bluo-gal(+) rKS56-lacZ cells were observed in the subcapsule in the rKS-SC group on day 5, and were further increased in number on day 9, accompanied by partial distribution in the corticomedullary junction, but not in the rKS-IA group. A portion of Bluo-gal(+) cells coexpressed Ki-67, aquaporin-1, hepatocyte growth factor (HGF), and c-Met. rKS-SC treatment significantly improved the tubular injury scores, ameliorated tubular cell apoptosis, and induced cell proliferation. The renal function also significantly improved in the rKS-SC group on day 5. These results demonstrate that locally implanted rKS56 cells could differentiate into tubular epithelial cells, thereby accelerating the recovery from tubular injury, most likely by producing tubular trophic factors. These results suggest the therapeutic potential of this novel approach for patients with end-stage renal failure.
INTRODUCTION
injury. Pax-2, which is expressed in the developing kidney, is reexpressed in regenerating renal tubules in a folic acid-induced ARF model (14) . Label-retaining Acute tubular necrosis is a common cause of acute renal failure (ARF), which is prevalent in many hospital-cells in the renal tubules that divide slowly contribute to the recovery of the injured tubules (23, 24) . Kidney-derived ized patients and is associated with high mortality (42). ARF is often reversible following appropriate treatment, side population (SP) cells contribute to tubular regeneration following cisplatin-induced ARF (8) . Renal papilla and the improvement of the renal function requires the recovery of injured tubules and the regeneration of func-contain a slow-cycling cell population involved in the tubular repair process, suggesting the renal papilla as a tional tubular epithelium. Recent reports have demonstrated that surviving cells residing around the injured niche for adult renal stem cells (35) . Intrarenal cells rather than bone marrow-derived cells are the main tubules may dedifferentiate, transdifferentiate, and rebuild the tubules (9) . Others have recently demonstrated source of renal recovery (22) . In addition, multipotent renal progenitor cells (MRPC) isolated from adult rat that bone marrow-derived cells could differentiate into mesangial cells (13, 15) , endothelial cells (12) , and renal kidney differentiate into renal tubules in a renal ischemia-reperfusion (I/R) model (5) . Collectively, these re-tubular epithelial cells (16, 21) . In addition, mesenchymal stem cells have also been demonstrated to have a ports suggest the essential role of the kidney to supply renal stem/progenitor cells following renal injury. potential for mediating a recovery from ARF (31) .
Certain cell populations in the adult kidney have been Highly proliferative cells were recently isolated from the S3 segment of the proximal tubules by microdissec-reported to regenerate tubular epithelial cells after renal 144 KINOMURA ET AL. tion (18) . These cells (designated as rKS56) exhibit a coated six-well dishes at a density of 1 × 10 5 cells per well in a 1:1 mixture of MCS and modified K1 medium cobblestone appearance, express proteins related to kidney development suggestive of an immature (undifferen-1 day prior to transfection. Next, rKS56 cells were transfected with 1 µg of pcDNA3.1/V5-His-TOPO/lacZ (In-tiated) phenotype, as well as proteins expressed in mature tubular epithelia. The rKS56 cells show a rapid vitrogen, San Diego, CA) by using Fugene-6 (Roche Diagnostic, Indianapolis, IN) according to the manufacturer's growth starting from a single cell, and differentiate into distinct nephron segments, thus suggesting the capacity instructions. In order to generate stably transfectant cells, cells were selected in a culture medium containing to undergo multiple differentiations. rKS56 cells injected into the rat renal parenchyma following I/R inte-500 µg/ml G418 (Sigma) until resistant colonies appeared. Thereafter, the colonies were trypsinized and grate into injured tubules and differentiate, suggesting rKS56 cells to serve as renal progenitor-like cells (18) . subcultured in a medium containing G418. A single cell was then plated into each well of 96-well plates, and cis-Diamminedichloroplatinum II (cisplatin) is a chemotherapeutic agent widely used for the treatment of cultured for 10 days. Wells with single colonies were marked, trypsinized, and divided into replicate wells of solid tumors. However, a common side effect of this agent is nephrotoxicity. Swelling, vacuolar degeneration, ne-two 96-well plates. After 3 days, one of these plates was stained using an X-gal staining kit (Roche Diagnostic) crosis, and desquamation of the tubular epithelial cells are observed mainly in the S3 segment (4, 29) in a rat according to the manufacturer's instruction. Colonies with uniform expression of β-gal (rKS56-LacZ cells) cisplatin-induced ARF model. Although the therapeutic effect of rKS56 cells is observed on tubular injury by were expanded from the replicate plates into flasks, and used in the following experiments. improved urinary N-acettyl-b-D-glucosaminidase (NAG) levels in an I/R model, no improvement of renal func-Bluo-gal Staining tion is seen (18) . In addition, the therapeutic effects of rKS56 cells in a cisplatin-induced ARF model remain to A monolayer of the rKS56 cells was washed once with PBS and then fixed in PBS containing 2% formal-be elucidated.
In the present study, the therapeutic effects of rKS56 dehyde and 0.25% glutaraldehyde for 10 min at 4°C. After fixation, the cells were washed three times with cells were investigated in a cisplatin-induced rat ARF model. The localization of LacZ-expressing rKS56 cells PBS, and 1 ml of Bluo-gal staining solution [5 mM K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 , 2 mM MgCl 2 , 20 mM was assessed, and the therapeutic efficacy via different methods of cell delivery was examined. In particular, a Tris-HCl, 0.01% Na deoxycholate, 0.02% Nonidet P-40, and 1 mg/ml Bluo-gal (Invitrogen) in PBS (pH 7.4)] was subcapsular cell injection approach was employed to avoid any potential mechanical injuries caused by intra-added and incubated for 6 h at 37°C. Light microscopic images were recorded using a microscope digital spot parenchymal injection. camera (Olympus, Tokyo, Japan).
MATERIALS AND METHODS
Similarly, Bluo-gal staining of the kidney was per-rKS56 Cell Culture formed as previously described with modifications (27). Sliced kidney tissues (2 mm thick) were fixed in ice-rKS56 cells were cultured in a 1: 
Establishment of rKS56 Cells Stably Transfected
was reverse-transcribed into cDNA and amplified using With the LacZ Gene a one-step RNA PCR kit (AMV; Takara Bio Inc., Shiga, Japan) and specific primer pairs for Pax-2, Musashi-1, In order to trace the implanted rKS56 cells in vivo, the cells were transfected with plasmid DNA encoding and GAPDH were subjected to agarose gel electrophoresis and visualized as previously described (18, 25) . bacterial β-galactosidase (β-gal) as previously described (26). The rKS56 cells were plated on type IV collagen-To examine the karyotype of rKS56-LacZ cells, the cells were studied in Nihon Gene Research Labs Inc. (PAS) for light microscopic observation. Twenty randomly selected fields were observed at a magnification (Sendai, Japan). Twenty rKS56-LacZ cells were analyzed by G-banding stain as previously described (18) . of 400×, and tubular injury was quantitated by scoring (grade 0 to 5): 0, normal; 1, tubular cells exhibiting des-Experimental Acute Renal Failure Model Induced quamation from the tubular basement membrane (TBM), by Cisplatin and Transplantation of rKS56-LacZ Cells swelling, vacuolar degeneration and necrosis involving <20% of the tubules; 2, 20-40% tubules were involved; The experimental protocol was approved by the Animal Ethics Review Committee of Okayama University 3, 40-60%; 4, 60-80%; and 5, 80-100%, as previously described with modifications (40, 48) . Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. Studies were performed on male SD rats (CLEA Japan, Tokyo, Japan) weighing 200-250 g. The
Immunohistochemical Staining animals had free access to tap water and standard rat Immunohistochemistry was performed as previously chow. Acute renal failure was provoked by a single IP described (11, 41) , utilizing Bluo-gal-stained and parafinjection of cisplatin (Sigma) at a dosage of 6 mg/kg fin-embedded sections (4 µm thick). After deparaffinizabody weight. A single IP injection of cisplatin at a dostion and rehydration, the sections were incubated with age of 6 mg/kg was preliminarily confirmed to be suffi-3% H 2 O 2 in methanol to inactivate endogenous peroxicient to induce histological alterations characterized by dase. Next, the sections were blocked with PBS containtubular injury, necrosis, and acute deterioration of renal ing 3% BSA and avidin/biotin Blocking Kit (Vector function by day 5. These alterations were reversible, and Laboratories, Burlingame, CA) followed by incubation renal function was significantly restored on day 9 after with rabbit polyclonal anti-AQP-1 (Chemicon, Temecula, the injection of cisplatin. rKS56-LacZ cells (1 × 10 6 CA, USA), type IV collagen (Chemicon), HGF (Institute cells/kidney) resuspended in 0.3 ml of saline were imof Immunology, Tokyo, Japan) antibodies or mouse planted into the subcapsule of the left kidney or the left monoclonal Ki-67 antibodies (DakoCytomation, Glosrenal artery 2 days after the injection of cisplatin. The trup, Denmark). Thereafter, the sections were incubated control group received saline in place of cell therapy with biotinylated secondary antibodies (Nichirei, Tokyo, in a similar manner. The SD rats were divided into the Japan), and immunoperoxidase staining was conducted following five subgroups: 1) untreated control (C; n = utilizing a Vectastain ABC Elite Reagent kit (Vector 5), 2) cisplatin-induced ARF treated by the implantation Laboratories). Diaminobenzidine (DAB) was used as a of rKS56 cells into the subcapsule (rKS-SC; n = 5), 3) chromogen. All slides were counterstained with hemacisplatin-induced ARF treated by the injection of saline toxylin. Normal mouse or rabbit IgG was used as a neg-(vehicle) into the subcapsule (V-SC; n = 5), 4) cisplatinative control. induced ARF treated by intra-arterial injection of rKS56
For the detection of proliferating cells incorporating cells (rKS-IA; n = 5), and 5) cisplatin-induced ARF BrdU, Bluo-gal-stained, paraffin-embedded sections (4 treated by the intra-arterial injection of vehicle buffer µm thick) were processed for immunohistochemistry us-(V-IA; n = 5). The body weight was measured on days ing a cell proliferation kit (Amersham Biosciences, 1, 2, 5, 7, 8, and 9 after the injection of cisplatin. The Buckinghamshire, UK) according to the manufacturer's SD rats were sacrificed on days 5 and 9 after the injecinstructions, and the sections were counterstained with tion of cisplatin. All rats received an IP injection of methyl-green (DAKO). The number of BrdU-positive BrdU (50 mg/kg; Sigma) 6 h before sacrifice. Kidneys cells in the outer stripe of the outer medulla was counted were obtained and processed for histological observain 20 randomly selected fields at a of magnification tion. Blood samples were drawn from the vena cava in-400× in each kidney section. ferior under anesthesia. Blood urea nitrogen (BUN) and serum creatinine levels were measured by SRL, Inc.
TUNEL Staining (Okayama, Japan). The serum creatinine levels were measured by the enzymatic colorimetric method as de-
The degree of tubular apoptosis was assessed using the in situ DNA nick end labeling (TUNEL) technique. scribed previously (41).
Bluo-gal-stained, paraffin-embedded sections (4 µm Histological Examination thick) were processed for immunohistochemistry using Apotag plus in situ Apoptosis Detection Kit (Chemicon) Because tubular injury was most evident in the outer stripe of the outer medulla in the cisplatin-induced ARF following the manufacturer's instructions, and counterstained with methyl-green (Dako). The number of model, the degree of proximal tubular injury in this area was assessed. The kidneys were removed, fixed in 10% TUNEL-positive cells in the outer stripe of the outer medulla was counted in 20 randomly selected fields at buffered formalin, and embedded in paraffin. Sections (3 µm thick) were stained with periodic acid-Schiff 400× magnification in each kidney section.
Statistical Analysis Incorporation of rKS56-LacZ Cells Into the Kidneys of Cisplatin-Induced ARF Rats
All values are expressed as the mean ± SEM. A In order to examine whether the transplanted rKS56-Kruskal-Wallis test with post hoc comparisons using LacZ cells possessed the ability to engraft into the kid-Scheffe's test was employed for intergroup comparisons ney following cisplatin-induced ARF, Bluo-gal staining of multiple variables. Statistical analysis was performed was performed. Rats receiving vehicle buffer, V-SC by StatView software (Abacus Concepts, Berkeley, CA).
( Fig. 3A) , or V-IA (data not shown) exhibited no β-A level of p < 0.05 was considered statistically signifigal(+) cells in the kidneys on day 9. In the rKS-SC cant.
group, β-gal(+) cells exhibiting a blue staining pattern were identified in the subcapsular area of the left kidney RESULTS on day 5 after the injection of cisplatin (data not shown).
Generation of rKS56-LacZ Cells Stably
On day 9, the subcapsular area was more thickened than Expressing β-gal that on day 5 in a diffuse manner ( Fig. 3B) and an increased number of β-gal(+) cells was observed in the In order to identify transplanted rKS56 cells in the subcapsular area ( Fig. 3C, D) , and focal Bluo-gal-posirecipient kidney, rKS56 cells stably expressing β-gal tive cells were also identified in the corticomedullary were established as described in Materials and Methods. junction ( Fig. 3E , F). However, no β-gal(+) cells were Although the rKS56 cells without transfection of LacZ observed in the kidneys of either the intra-arterial injecremained unstained ( Fig. 1A) , rKS56-LacZ cells exhibtion (rKS-IA) group or the vehicle-injected group (data ited blue cytoplasmic staining in Bluo-gal ( Fig. 1B) and not shown). X-gal ( Fig. 1C ) staining assay. rKS56-LacZ cells exhibited a cobblestone appearance similar to rKS56 cells.
rKS56-LacZ Cells Implanted at the Subcapsule The expression of Musashi-1 mRNA, the marker for Following the Induction of ARF Proliferate neural stem cells, and Pax-2, which is involved in the and Differentiate Into Tubular Epithelial Cells development of the kidney, was also examined by RTin the Cisplatin-Induced ARF Model PCR. rKS56 cells express these proteins, which appear
To examine whether the incorporated rKS56-LacZ to have a phenotype similar to that of renal progenitorcells can proliferate and differentiate into mature renal like cells and immature neural stem-like cells (18) . Both tubular epithelial cells, Bluo-gal staining followed by rKS56 and rKS56-LacZ cells expressed mRNAs for Muimmunohistochemistry was performed for Ki-67 (a sashi-1 and Pax-2 (Fig. 1D ). The rKS56-LacZ cells conknown marker for cell proliferation), AQP-1 (a transtained 68-71 chromosomes and are considered to be porter protein expressed in the proximal tubular epithenearly triploid, similar to rKS56 cells (18) (Fig. 1E ). lial cells), and type IV collagen (a major constituent of There was no apparent difference in the growth rate bethe basement membrane). A portion of Bluo-gal(+) cells tween rKS56 and rKS56-LacZ cells (data not shown), (35.5%) in the subcapsule coexpressed AQP-1 (Fig. suggesting that rKS56-LacZ cells maintain the charac-4A). In the corticomedullary junction, Bluo-gal(+) cells teristics of rKS56 cells as renal progenitor-like cells.
weakly coexpressed AQP-1, and adjacent tubular epithe-These results collectively demonstrate that the phenolial cells expressed AQP-1 more intensely (Fig. 4B ) in type of rKS56-LacZ cells is similar to that of rKS56 the rKS-SC group. On day 9 after the induction of ARF, cells.
a portion of Bluo-gal(+) cells coexpressed Ki-67 in the subcapsular area [28.9% of total Bluo-gal(+) cells] (Fig.
Changes in Body Weight
4C) and the corticomedullary junction ( Fig. 4D ) in the rKS-SC group, suggesting the potential migratory and Perez et al. demonstrated that renal dysfunction and loss in body weight are prevented by treatment with reti-proliferative capacity of rKS56-LacZ cells. A basement membrane structure containing type IV collagen was ob-noic acid in the potassium dichromate-induced ARF model (36) . In the present cisplatin-induced ARF model, served in the basolateral side of the Bluo-gal(+) cells in both the subcapsule ( Fig. 4E ) and the corticomedullary body weight decreased until day 5 due to disturbed urine concentration capacity caused by tubular injury, and junction ( Fig. 4F ). Previous reports described the role of HGF in tubulo-then increased as renal function returned to the level close to that in normal animals (Fig. 2 ). In the rKS-genesis and the therapeutic role of HGF in various models of renal disease including the ARF model induced SC group, the mean body weight tended to be higher in comparison to the other groups, suggesting the potential by ischemia and reperfusion and a spontaneous mouse model for chronic renal disease (ICGN strain) (28, 30) . therapeutic effects of the subcapsular delivery of rKS56-LacZ cells on disturbed tubular concentration function To examine the potential involvement of secreted factors in the observed therapeutic effects of rKS56-LacZ cells, (Fig. 2) . 6A) , and rKS-SC treatment resulted in a significant re-prominently in the corticomedullary junction (46) . Similarly, on day 5 after the injection of cisplatin, swelling duction of apoptotic cells (Fig. 6C) . No inhibitory effect on cisplatin-induced tubular apoptosis was observed in and detachment of tubular epithelial cells were observed most remarkably in the corticomedullary junction in the the V-IA (Fig. 6D) or the rKS-IA group (Fig. 6E ). The number of apoptotic cells on day 9 was lower in com-V-SC group (Fig. 5B ), and these alterations were mildly decreased on day 9 (Fig. 5F ). rKS-SC treatment mildly parison to that on day 5 in the V-SC (Fig. 6F) or the V-IA (Fig. 6H ) group, and treatment with rKS56-LacZ ameliorated the degree of tubular injury on day 5 (Fig.  5C ), and resulted in the appearance of flat regenerative cells did not show an inhibitory effect ( Fig. 6G, I, J) . The proliferation of tubular epithelial cells was quan-tubular epithelial cells observed in the majority of injured tubules on day 9, leading to marked amelioration titatively evaluated by immunohistochemistry for BrdU. The number of BrdU(+) cells in the corticomedullary of tubular injury (Fig. 5G) .
The histopathological alterations were analyzed by junction was significantly increased in the V-SC (Fig.  7B ) group on day 5 after the induction of ARF in com-scoring the necrotizing tubules as described in Materials and Methods. The tubular injury score was significantly parison to the untreated control ( Fig. 7A ). rKS-SC treatment ( Fig. 7C ) resulted in a significant increase of the lower in the rKS-SC group on days 5 and 9 in comparison to the V-SC group at a corresponding time point BrdU(+) cell number in comparison to the V-SC group, although V-IA ( Fig. 7D ) or rKS-IA ( Fig. 7E ) treatment (Fig. 5J) . No significant improvement of the tubular injury score was observed in either the rKS-IA or the V-did not exhibit such an effect. On day 9, the number of BrdU(+) cells in the V-SC group (Fig. 7F ) was lower IA group (Fig. 5D , E, H, I). than that on day 5, and rKS-SC ( Fig. 7G ) treatment re-next examined. The serum creatinine and BUN levels were significantly elevated in the V-SC group on day 5 sulted in a significant increment of the BrdU(+) cell number, although V-IA ( Fig. 7H ) or rKS-IA (Fig. 7I) after the induction of ARF in comparison to the untreated control (Fig. 8 ). rKS-SC treatment resulted in a treatment did not exhibit such an effect. 72.2 ± 1.8, V-IA 102.0 ± 16.7, rKS-IA 108.3 ± 11.7 mg/ the S3 segment using a microdissection technique and were established from a single cell clone, indicating dl). On day 9, the renal function had mostly recovered in all the groups without showing any significant differ-their pure and homogeneous origin. Therefore, rKS56 cells are distinct from side population cells or mesen-ence. The parameters for liver function and urinary protein levels were not significantly different among the ex-chymal stem cells, previously reported to exhibit therapeutic effects in ARF models, because these cell popula-perimental groups (data not shown).
tions may consist of several different cell types. However, DISCUSSION no improvement of renal function was observed following the implantation of rKS56 cells in the ARF model, Recent advances in regenerative medicine have demonstrated the therapeutic potential of cell therapy em-potentially due to the intrarenal injection technique utilized in the previous study (18) . In addition, to follow ploying stem/progenitor cells for the treatment of various disorders (6, 19, 38, 44) . The differentiation of bone the fate of implanted rKS56 cells in vivo, it would be convenient if these cells permanently expressed marker marrow-derived stem cells (12, 13, 15, 16, 21) and mesenchymal stem cells into renal cells has been described. In proteins.
In the present study rKS56-LacZ cells were estab-addition, therapeutic approaches employing these somatic stem cells show favorable effects in ARF models lished, which permanently expressed β-gal, in order to track the destination of the implanted cells. The rat cis- (7, 16, 43) . Recent reports further describe the therapeutic efficacy of the side population cells or the label-retain-platin-induced ARF model, an established experimental model with highly reproducible tubular injuries, was ing cells derived from the adult kidney in ARF models (8, 24) . employed to evaluate the therapeutic effects of rKS56-LacZ cells. A previous study recently reported the isolation and establishment of rKS56, rat renal progenitor-like cells
The characteristic features of rKS56 cells include the expression of factors involved in renal development (18) . rKS56 cells exhibit the capacity to differentiate into a mature tubular epithelial cell phenotype and to such as Pax-2 and Wnt-4, suggestive of an immature, undifferentiated, phenotype (18) . Interestingly, rKS56 undergo self-renewal. rKS56 cells were isolated from cells also express Musashi-1, a neural RNA binding pro-were implanted using the intra-arterial (45) or intravenous (12, 16, 21) approach in one ARF model, and kid-tein and a known marker for neural stem cells, suggestive of an immature phenotype (18) . Musashi-1 is also ney-derived SP cells were injected intravenously, leading to homing into the renal interstitium (8) . In another required for the asymmetric division of the sensory organ precursor cells (32) and, therefore, its expression in report, CD133(+) cells were isolated from the tubular fractions, and implanted using the intrarenal approach, rKS56 cells may suggest their potential for self-renewal. The highly proliferative nature of rKS56 cells was also leading to therapeutic effects in an ARF model (1) . Recently, Sagrinati et al. demonstrated that the IV injection observed in rKS56-lacZ cells, stably expressing β-gal. In addition, rKS56-LacZ cells expressed Pax-2 and Mu-of human parietal epithelial cells expressing stem cell markers CD24 and CD133 successfully regenerated in-sashi-1, similar to the original rKS56 cells, suggesting the maintenance of the phenotype of rKS56-LacZ cells jured renal tubules (39) . Dekel et al. demonstrated that kidney precursor cells derived from early embryos and as renal progenitor-like cells. According to a karyotype analysis, rKS56-LacZ cells were observed to be nearly fetal tissue differentiated into functional nephrons by the implantation of cells under the renal capsule (2) . Ac-triploid, similar to rKS56 cells. These results suggest that the characteristics of rKS56 cells are not changed cording to these previous reports, the efficiency of the incorporation of rKS56-LacZ cells delivered by various following the transfection of the LacZ gene. However, it is unknown at which time point the karyotype of approaches was examined. Based on the observations of this study, the implantation of rKS56-LacZ cells at the rKS56 cells change from diploid to triploid. An earlier study confirmed that subcutaneously implanted rKS56 subcapsule leads to the most efficient engraftment and facilitates the migration of the implanted cells from the cells did not result in formation of any tumor-like mass in nude mice, indicating that rKS56 cells do not possess subcapsule to the corticomedullary junction, the area close to the origin of rKS56-LacZ cells (S3 segment of a tumor cell phenotype (18) .
The therapeutic efficacy of rKS56-LacZ cells was ex-renal tubules). The cells were injected on day 2 after the induction of cisplatin-induced ARF, considering the amined in a cisplatin-induced ARF model. Initially, the localization of implanted rKS56-LacZ cells was evalu-potential cytotoxic influence of cisplatin on implanted rKS56-LacZ cells. Although the incorporation of Bluo-ated. The Bluo-gal staining method was used to detect the intrarenal localization of cells expressing β-gal due gal(+) rKS56-LacZ cells could not be identified in the kidneys of animals receiving intra-arterial injection, the to the specificity of this method, because nonspecific positive staining of rat kidney tissue was observed in introduction of cells at an earlier time point might have resulted in the engraftment of rKS56-LacZ cells. This the case of X-gal staining. Although Bluo-gal(+) rKS56-LacZ cells were not identified in animals receiving intra-possibility requires further investigation.
In the cisplatin-induced ARF model, the corticomed-arterial cell injection, engraftment of rKS56-LacZ cells was observed in the subcapsule and, to a lesser extent, ullary junction area is the most severely injured nephron segments. The tubular injury score in this area signifi-in the corticomedullary junction area by subcapsular cell implantation. rKS56-LacZ cells were implanted in the cantly improved in the rKS-SC group in comparison to that in the V-SC group, thus suggesting the potential renal subcapsule to avoid direct mechanical injury to the renal parenchyma. With this approach, implanted rKS56-contribution of rKS56-LacZ cells engrafted in this area. Tubular apoptosis was ameliorated in the rKS-SC group LacZ cells were widely distributed at the renal subcapsule. The potential engraftment of distinct renal tubular in comparison to the V-SC group, and the rKS-SC group exhibited an increment of BrdU(+) proliferating cells in epithelial cells could not be evaluated in the present study, because there were no available tubular epithelial comparison to other groups. The beneficial effects of rKS-SC treatment on preventing tubular apoptosis sug-cells derived from the SD rat. The proliferation and tubular differentiation of implanted rKS56-LacZ cells gest the potential secretion of survival factors from implanted rKS56-LacZ cells. Although the therapeutic ef-were further confirmed by double immunohistochemistry for Ki-67, AQP-1, and type IV collagen. In addition, fects on apoptosis were not observed on day 9, the effect of rKS-SC treatment on promoting cell proliferation re-the number of Bluo-gal(+) cells on day 9 was apparently increased in comparison to that on day 5, and Bluo-gal(+) mained remarkable on day 9. It is possible that engrafted rKS56-LacZ cells divided and contributed to the incre-cells in the corticomedullary junction were observable on day 9, further supporting the in situ proliferation and ment of BrdU(+) proliferating cells even at the later time point. migration of implanted rKS56-LacZ cells toward tubular regions injured by cisplatin.
Although a portion of Bluo-gal(+) cells observed in the corticomedullary junction was positive for AQP-1, There are numerous recent reports addressing the delivery approaches of stem/progenitor cells for treating tubular epithelial cells adjacent to the Bluo-gal(+) cells tended to be intensely immunoreactive for AQP-1. renal injury. For example, bone marrow-derived cells These results suggest that rKS56-LacZ cells might have diabetic nephropathy, and nephrosclerosis, predispose the patient to end-stage renal disease (ESRD), and com-replaced the injured tubular epithelial cells, partially maintaining the progenitor-like immature phenotype, mon histological alterations in ESRD are glomerulosclerosis and tubulointerstitial fibrosis. At the advanced and promoted the regeneration and differentiation of surviving adjacent cells by producing paracrine growth fac-stage of chronic renal disease, the microenvironments surrounding the resident renal cells are greatly altered tors. The number of Bluo-gal(+) cells coexpressing AQP-1 might therefore increase at a later time point, thus with different components of extracellular matrix proteins. At this stage, implanted stem/progenitor cells may reflecting the terminal differentiation of incorporated rKS56-LacZ cells. not engraft, survive, and proliferate due to the altered "niche" and the scaffold of the kidney. Therefore, thera-A recent report demonstrated that the IV injection of kidney-derived SP cells leads to the distribution of these peutic approaches employing scaffold proteins in combination with stem/progenitor cells may be ideal for cells in the renal interstitium in a ARF model (8) . Because rKS56-LacZ cells were injected at the subcapsule, treating advanced renal disorders. Yokoo et al. reported successful kidney organogenesis from human mesenchy-it is possible that rKS56-LacZ cells migrated out of the subcapsule through the interstitial space, and were fi-mal stem cells using a growing rodent embryo (47) .
Considering the scaffold of the renal component cells to nally incorporated into the injured tubules in the corticomedullary junction. However, no Bluo-gal(+) cells re-be altered in the advanced stage of renal disorders, such therapeutic strategies would be promising. In another re-maining in the interstitial area were identified, thus potentially suggesting the rapid tubular engraftment of port, implantation of bone marrow cells 7 days after inducing rat progressive glomerulosclerosis improved re-the rKS56-LacZ cells.
The renal function on day 5 was significantly im-nal function and mortality (20) and implantation of mesenchymal stem cells into mice lacking the α3-chain proved by rKS56-SC treatment, in line with therapeutic effects on tubular cell injury, apoptosis, and cell prolif-of type IV collagen prevented the loss of peritubular capillaries and reduced renal fibrosis (34). Collectively, eration. Considering the relatively limited number of Bluo-gal(+) cells in the corticomedullary junction area, these reports suggest that strategies employing renal stem/progenitor cell implantation would be effective rKS56-LacZ cells may exhibit renoprotective effects by producing growth factors, rather than directly replacing when structural alteration of kidney has not fully developed. Further studies on the therapeutic effects of the injured tubules. On day 9, the recovery of renal function was observed in all the experimental groups, consistent implantation of rKS56-LacZ cells in a chronic renal disease model are presently under way. with the natural course of the cisplatin-induced ARF model. Previous studies have demonstrated that HGF
In conclusion, the implantation of rKS56-LacZ cells at the renal subcapsule resulted in the amelioration of (17,30,37), epidermal growth factor (10), and insulin-like growth factor (3) may contribute to renal tubular repair acute renal damage induced by cisplatin. Considering the large population of patients with chronic kidney dis-following various injuries. Another report demonstrated that adult human mesenchymal stem cells express HGF ease (CKD), the number of patients with malignant tumors receiving cisplatin complicated by acute renal and the HGF receptor, c-Met (33) . Immunohistochemical analysis revealed that a portion of Bluo-gal(+) cells failure may be increased. Although further basic experimental approaches are necessary for therapeutic applica-coexpressed HGF, supporting the hypothesis that the therapeutic effects of rKS56-LacZ cells were mediated, tion in the clinical setting, cell therapy employing adult kidney-derived stem/progenitor cells appears to be ad-at least in part, via a paracrine mechanism. In addition, trophic factors produced by the implanted rKS56-LacZ vantageous over therapeutic strategies employing embryonic tissue stem cells, considering the limited com-cells might have affected themselves in an autocrine manner, thus resulting in the regeneration of tubular epi-mitment of renal stem/progenitor cells toward renal lineage and the circumvention of ethical issues related thelial cells and/or resident tubular progenitor cells. Future analysis may clarify potential factors responsible for to embryos. the observed renoprotective effects produced by rKS56-
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